Letrozol Jgl 2,5 Mg (Letrozole)

Letrozole is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

• Hormone receptor‑positive breast cancer: reduces tumor growth in postmenopausal women.
• Adjuvant therapy for early‑stage disease: lowers risk of recurrence after surgery.
• Metastatic breast cancer: prolongs progression‑free survival in advanced disease.

• Letrozole selectively binds to the aromatase enzyme, blocking the conversion of androstenedione and testosterone into estrone and estradiol. By inhibiting estrogen synthesis, systemic estrogen levels fall, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing or halting cancer progression.

Letrozole may cause a range of adverse reactions.

Common Side Effects

• Hot flashes: sudden feeling of warmth and sweating.
• Joint and muscle pain: aching in limbs or back.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: mild to moderate upset stomach.
• Headache: pressure or throbbing pain.
• Increased sweating: excessive perspiration.

Serious or Rare Side Effects

• Osteoporosis or bone loss: increased fracture risk.
• Cardiovascular events: hypertension, thromboembolism.
• Liver function abnormalities: elevated enzymes or hepatitis.
• Severe allergic reactions: rash, swelling, anaphylaxis.
• Pulmonary embolism: sudden shortness of breath.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Bone health assessment: perform baseline densitometry and consider calcium/vitamin D supplementation.
• Liver function monitoring: check transaminases periodically.
• Cardiovascular risk review: assess blood pressure and lipid profile.
• Pregnancy avoidance: letrozole is contraindicated in pregnancy (Category X).
• Hepatic impairment caution: dose adjustment may be required in severe liver disease.
• Storage at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines that affect its metabolism or hormonal pathways.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase letrozole exposure.
• Estrogen‑containing hormone therapy: antagonizes letrozole’s effect.
• Certain antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: may alter anticoagulant control.
• Statins: potential for increased muscle toxicity.
• SSRIs and SNRIs: possible additive effects on mood or fatigue.
• Glucocorticoids: may affect bone health when combined.
• NSAIDs: monitor for gastrointestinal irritation.